Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators
Authors:
- 1 November 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 12 (11) , e007600
Abstract
Background: In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increased morbidity and mortality. Therefore, we conducted this study to evaluate the efficacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular tachyarrhythmias (VT) in patients with an ICD. Methods: An electronic database search for randomized controlled trials that evaluated antiarrhythmic drugs and CA in patients with ICD was conducted. The primary outcome was recurrent VT. Secondary outcomes were ICD shocks and any deaths. Bayesian and frequentist network meta-analyses were performed to calculate hazard ratios (HRs) and 95% credible intervals (CrIs)/CIs. Results: Twenty-two randomized controlled trials were identified (3828 total patients; age 64.3±11.4; 79% males). The use of amiodarone was associated with a significantly reduced rate of VT recurrence compared with control (HR=0.34 [95% CrI=0.15–0.74]; absolute risk difference=−0.23 [95% CrI=−0.23 to −0.09]; number needed to treat=4). Sotalol was associated with increased risk of VT recurrence compared with amiodarone (HR=2.88 [95% CrI=1.35–6.46]). Compared with control, amiodarone (HR=0.33 [95% CrI=0.15–0.76]; absolute risk difference=−0.17 [95% CrI=−0.32 to −0.06]; number needed to treat=6) and CA (HR=0.52 [95% CrI=0.30–0.89; absolute risk difference=−0.12 [95% CrI=−0.24 to −0.03]; number needed to treat=8) were associated with significantly reduced ICD shocks. Compared with amiodarone, sotalol was associated with significantly increased ICD shocks (HR=2.70 [95% CrI=1.17−6.71]). The rate of death was not significantly different between the competing strategies. The node-splitting method showed no inconsistency. Conclusions: Among patients with an ICD, amiodarone significantly reduced VT recurrence and ICD shocks, while CA reduced ICD shocks. Sotalol significantly increased VT recurrence and ICD shocks compared with amiodarone. The long-term side effects of amiodarone and early complications of CA should be weighed carefully according to specific patient characteristics.Keywords
This publication has 44 references indexed in Scilit:
- Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart diseaseHeart Rhythm, 2011
- Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Heart Rhythm, 2011
- Characterization of the Arrhythmogenic Substrate in Ischemic and Nonischemic CardiomyopathyJACC, 2010
- Prophylactic Catheter Ablation for the Prevention of Defibrillator TherapyNew England Journal of Medicine, 2007
- Causes and Consequences of Heart Failure After Prophylactic Implantation of a Defibrillator in the Multicenter Automatic Defibrillator Implantation Trial IICirculation, 2006
- Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter DefibrillatorCirculation, 2004
- Randomized controlled trial of ventricular tachycardia treatment by cooled tip catheter ablation vs drug therapyJACC, 1998
- Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillatorsJACC, 1996
- Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial)The American Journal of Cardiology, 1994
- Effects of chronic amiodarone therapy on defibrillation thresholdThe American Journal of Cardiology, 1992